Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.1.01944
European Journal of Endocrinology, Vol 153, Issue 1, 99-106
Copyright © 2005 by European Society of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dolz;an, V
Right arrow Articles by Battelino, T
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dolz;an, V
Right arrow Articles by Battelino, T

CLINICAL STUDY

Mutational spectrum of steroid 21-hydroxylase and the genotype-phenotype association in Middle European patients with congenital adrenal hyperplasia

V Dolz;an1, J Sólyom3, G Fekete3, J Kovács4, V Rakosnikova5, F Votava5, J Lebl5, Z Pribilincova6, SM Baumgartner-Parzer7, S Riedl8, F Waldhauser8, H Frisch8, M Stopar-Obreza2, C Krz;isnik2 and T Battelino2

1 Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia, 2 University Children’s Hospital, Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases, Vrazov trg 1 SI-1000, Ljubljana, Slovenia, 3 2nd Department of Paediatrics, Semmelweis University, Budapest, Hungary, 4 Department of Paediatrics, University of Szeged, Szeged, Hungary, 5 Department of Paediatrics, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic, 6 Department of Paediatrics, Comenius University, Bratislava, Slovakia, 7 Department of Internal Medicine III, Division of Endocrinology and Metabolism, Medical University, Vienna, Austria and 8 Department of Paediatrics, Medical University, Vienna, Austria

(Correspondence should be addressed to T Battelino; Email: tadej.battelino{at}mf.uni-lj.si)

Objective: To analyze the mutational spectrum of steroid 21-hydroxylase (CYP21) and the genotype– phenotype correlation in patients with congenital adrenal hyperplasia (CAH) registered in the Middle European Society for Pediatric Endocrinology CAH database, and to design a reliable and rational approach for CYP21 mutation detection in Middle European populations.

Design and methods: Molecular analysis of the CYP21 gene was performed in 432 CAH patients and 298 family members. Low-resolution genotyping was performed to detect the eight most common point mutations. High-resolution genotyping, including Southern blotting and sequencing was performed to detect CYP21 gene deletions, conversions, point mutations or other sequence changes.

Results: CYP21 gene deletion and In2 and Ile172Asn mutation accounted for 72.7% of the affected alleles in the whole study group. A good genotype–phenotype correlation was observed, with the exception of Ile172Asn and Pro30Leu mutations. In 37% of patients low resolution genotyping could not identify the causative mutation or distinguish homozygosity from hemizygosity. Using high-resolution genotyping, the causative mutations could be identified in 341 out of 348 analyzed patients. A novel mutation Gln315Stop was found in one simple virilising CAH (SV-CAH) patient from Austria. In the remaining seven patients polymorphisms were identified as the leading sequence alteration. The presence of elevated basal and ACTH-stimulated 17-hydroxyprogesterone, premature pubarche, advanced bone age and clitoral hypertrophy directly implicated Asn493Ser polymorphism in the manifestation of nonclassical- (NC) and even SV-CAH.

Conclusions: By genotyping for the most common point mutations, CYP21 gene deletion/conversion and the 8 bp deletion in exon 3, it should be possible to identify the mutation in 94–99% of the diseased alleles in any investigated Middle European population. In patients with a mild form of the disease and no detectable mutation CYP21 gene polymorphisms should be considered as a plausible disease-causing mutation.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
C. Moran, R. Azziz, N. Weintrob, S. F. Witchel, V. Rohmer, D. Dewailly, J. A. M. Marcondes, M. Pugeat, P. W. Speiser, D. Pignatelli, et al.
Reproductive Outcome of Women with 21-Hydroxylase-Deficient Nonclassic Adrenal Hyperplasia
J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3451 - 3456.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 European Society of Endocrinology.